|
|
Links
Home FDA Information MedlinePlus |
AbilifyThis page contains recent news articles, when available, and an overview of Abilify (aripiprazole) but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Aripiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used to treat episodes of mania (frenzied, abnormally excited or irritated mood) or mixed episodes (symptoms of mania and depression that happen together) in patients with bipolar I disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. Recent news articles mentioning Abilify AstraZeneca's Seroquel Will Overtake GlaxoSmithKline's Lamictal by ... - Feb 20, 2007 Earthtimes.org ..."During the next 10-15 years, we expect that only two other therapies will receive labeling for the treatment of bipolar depression: BMS/Otsuka's Abilify firm in cannabis breakthrough - Feb 14, 2007 Guardian Unlimited, It has had great success with its CNS product ABILIFY for schizophrenia which it took from launch to $1.9bn of sales in four years. BiPolar - The New "Must-Have" Disorder - Feb 2, 2007 Huffington Post, I was surprised recently by a television commercial from Bristol-Myers Squibb for ABILIFY® (aripiprazole). While I've gotten used to the daily implications Street split on Bristol-Myers - Jan 25, 2007 Monsters and Critics.com, Abilify and Reyataz both posted strong performances. Abilify sales jumped 62 percent to $362 million while Reyataz sales rose 36 percent to $255 million. Bristol-Myers Squibb Company Reports Financial Results for the ... - Jan 25, 2007 Yahoo! News (press release) Total revenue for ABILIFY®, an antipsychotic agent for the treatment of schizophrenia, acute bipolar mania and bipolar disorder, increased 62%, GW Pharma signs partner for cannabis drug in US - Feb 14, 2007 Scotsman, Its biggest product is schizophrenia drug Abilify, which is made and sold by Bristol-Myers Squibb . GW said it was also in talks with Otsuka over a research FDA handling of Lilly drug needs probe: scientist - Feb 13, 2007 ABC News Antipsychotics include Bristol-Myers Squibb's Abilify, Novartis AG's Clozaril, Lilly's Symbyax, AstraZeneca Plc's Seroquel, Johnson & Johnson's Risperdal Sanofi Hit By Bureaucracy - Feb 13, 2007 Forbes, They include Abilify for schizophrenia and bipolar disorder, Reyataz for HIV, Orencia for rheumatoid arthritis and Sprycel for chronic myelogenous leukemia. Why Antipsychotics Cause Weight Gain - Feb 12, 2007 Wall Street Journal (subscription), ...metabolic changes, including weight gain and cholesterol levels. The drug is marketed as Abilify by Bristol-Myers Squibb & Co. and Otsuka Pharmaceutical Co. Eli Lilly & Co.'s fourth-quarter net income fell 81%, hurt by ... - Jan 31, 2007 Wall Street Journal (subscription), ...s Abilify, which had fourth-quarter sales of $362 million world-wide. Total Zyprexa sales in 2006 were $4.36 billion. Lilly said a US appeals court upheld Bristol reports loss in quarter - Jan 26, 2007 Los Angeles Times, Sales of schizophrenia drug Abilify jumped 62% to $362 million, helped by growing demand in Europe and the drug's reputation for not causing weight gains Bristol-Myers posts 4Q loss on sinking Plavix sales, onetime charge - Jan 25, 2007 San Diego Union Tribune, Revenue from AIDS drug Reyataz rose 36 percent to $255 million while sales from anti-psychotic Abilify grew 62 percent to $362 million. Bristol-Myers posts loss on litigation reserves - Jan 25, 2007 MarketWatch Meanwhile, sales of the hypertension medication Avapro rose 11% to $307 million, while sales of the antipsychotic drug Abilify jumped 62% to $362 million. Bristol-Myers Records Loss After Plavix Sales Drop (Update8) - Jan 25, 2007 Bloomberg Abilify for schizophrenia rose 62 percent to $362 million. Sales of Sprycel, approved in June to treat two rare cancers of the blood and bone marrow, Bristol-Myers Records Loss After Plavix Sales Drop (Update7) - Jan 25, 2007 Bloomberg Abilify for schizophrenia rose 62 percent to $362 million. Bristol-Myers said last month it plans to file this year for US approval of the breast-cancer Amid Litigation-Reserve Boost - Jan 25, 2007 Wall Street Journal (subscription), Bristol-Myers sales were helped by schizophrenia drug Abilify, which surged 62% to $362 million world-wide. AIDS treatment Reyataz rose 36% and cancer Bristol-Myers Records Loss After Plavix Sales Drop (Update4) - Jan 25, 2007 Bloomberg Abilify for schizophrenia rose 62 percent to $362 million.. Bristol-Myers said last month it plans to file this year for US approval of the breast-cancer B-MS hopes the pain caused by generic Plavix will end soon - Jan 26, 2007 Pharma Times (subscription), Nevertheless there were some bright spots for B-MS, notably the performance of the antipsychotic Abilify (aripiprazole), up 62% to $362 million and The Bristol takes a hit as Plavix sales drop - Jan 25, 2007 Newark Star Ledger, Revenue from AIDS drug Reyataz rose 36 percent, to $255 million, while sales from anti- psychotic Abilify grew 62 percent, to $362 million. Bristol-Myers posts 4Q loss on sinking Plavix sales, onetime charge - Jan 25, 2007 Brandon Sun, Revenue from AIDS drug Reyataz rose 36 per cent to $255 million while sales from anti-psychotic Abilify grew 62 per cent to $362 million. Bristol-Myers posts 4th-quarter loss - Jan 25, 2007 Herald News Daily, Revenue from AIDS AIDS drug Reyataz rose 36 percent to $255 million while sales from anti-psychotic Abilify grew 62 percent to $362 million. Earnings Preview: Bristol-Myers Squibb - Jan 23, 2007 Forbes, The analyst forecast sales of anti-psychotic medication Abilify to grow 47 percent to $330 million, and HIV drug Reyataz to increase 30 percent to $244 Earnings: Yahoo, Sun Microsystems, AMD, More... - Jan 23, 2007 FOX News ...s (BMY) newer Abilify. Sales of Topamax jumped 28 percent to $529 million. Sales of arthritis drug Remicade grew 13 percent to $780 million, while those of How should Abilify be used? [MedMaster Patient Drug Information database] Aripiprazole comes as a tablet and a solution (liquid) to take by mouth. It is usually taken once a day with or without food. Take aripiprazole at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take aripiprazole exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor may start you on a low dose of aripiprazole and increase your dose after at least 2 weeks. Aripiprazole controls schizophrenia but does not cure it. It may take 2 weeks or longer before you feel the full benefit of aripiprazole. Continue to take aripiprazole even if you feel well. Do not stop taking aripiprazole without talking to your doctor. Other uses for Abilify [MedMaster Patient Drug Information database] Before taking alosetron,
What side effects can Abilify cause? [MedMaster Patient Drug Information database] Aripiprazole may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. The following symptoms are uncommon, but if you experience any of them or those listed in the SPECIAL PRECAUTIONS section, call your doctor immediately:
Aripiprazole may cause other side effects. Call your doctor if you have any unusual problems while taking this medication. If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online [at http://www.fda.gov/MedWatch/report.htm] or by phone [1-800-332-1088]. Brand names for Abilify [MedMaster Patient Drug Information database]
|